Drug development targeting the glycogen synthase kinase-3β (GSK-3β)-mediated signal transduction pathway: Role of GSK-3β in myocardial protection against ischemia /reperfusion injury

Journal of Pharmacological Sciences

Volumn 109, Issue 2, 2009, Pages 162-167

  Miura, Tetsuji ^a   Nishihara, Masahiro ^a   Miki, Takayuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycogen synthase kinase 3 (GSK 3 ); Mitochondria; Mitochondrial permeability transition pore; Myocardial infarction; Signal transduction

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; CHELERYTHRINE; CYCLOPHILIN D; CYCLOSPORIN A; ERYTHROPOIETIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; ISOFLURANE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN INHIBITOR; PROTEIN P53; SANGLIFERIN A; SOMATOMEDIN; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; WORTMANNIN; CARRIER PROTEIN; GLYCOGEN SYNTHASE KINASE 3;

ACUTE HEART INFARCTION; DRUG EFFECT; DRUG TARGETING; ENZYME INACTIVATION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REPERFUSION INJURY; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; DRUG DELIVERY SYSTEM; METABOLISM; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NECROSIS; RATS; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 65449182366     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R27FM     Document Type: Short Survey

References (46)

1. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577-595.
2. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3:479-487.
3. Mora A, Sakamoto K, McManus EJ, Alessi DR. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett. 2005;579:3632-3638.
4. Sugden PH, Fuller SJ, Weiss SC, Clerk A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hyper- trophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol. 2008;153 Suppl 1:S137-S153.
5. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3/β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549.
6. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphoryla- tion of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res. 2002;90:377-379.
7. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase-3/ inhibition during reper- fusion in intact rat hearts. Circ Res. 2004;94:960-966.
8. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3/β by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 2008;117:2761-2768.
9. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3?. Am J Physiol Heart Circ Physiol. 2006;291: H748-H755.
10. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3β-mediated myocardial protection. J Mol Cell Cardiol. 2007;43:564-570.
11. Piper HM, Abdallah Y, Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res. 2004;61:365-371.
12. Rodriguez-Sinovas A, Abadallah Y, Piper HM, Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev. 2007;12:207-216.
13. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
14. Matsumoto T, Miura T, Miki T, Genda S, Shimamoto K. Blockade of the Na+-Ca2+ exchanger is more efficient than blockade of the Na+-H+ exchanger for protection of the myocardium from lethal reperfusion injury. Cardiovasc Drugs Ther. 2002;16:295-301.
15. Forster K, Paul I, Solenkova N, Staudt A, Cohen MV, Downey JM, et al. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol. 2006;101:319-326.
16. Vinten-Johansen J, Zhao Z-Q, Jiang R, Zatta AJ, Dobson GP. Preconditioning and postconditioning: innate cardioprotection from is chemia-reperfusion injury. J Appl Physiol. 2007;103:1441-1448.
17. Miura T. Myocardial Infarction. In: Sperelakis N, editor. Physiology and pathophysiology of the heart, 3rd ed. Norwell: Kluwer Academic Publisher; 1994. p. 1125-1145.
18. Komuro I, Ohtsuka M. Forefront of Na+/Ca2+ exchange studies: Role of Na+/Ca2+ exchanger - lessons from knockout mice. J Pharmacol Sci. 2004;96:23-26.
19. Inserte J, Gacrcia-Dorado D, Hernando V, Barba I, Soler-Soler J. Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion. Cardiovasc Res. 2006;70:364-373.
20. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res. 2004;61:372-385.
21. Crompton M. Mitochondrial intermembrane junctional complexes and their role in cell death. J Physiol. 2000;529 Pt 1:11-21.
22. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J. 1995;307:93-98.
23. Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi P, et al. Transient and long-lasting opening of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J. 1999;76:725-734.
24. Kim JS, Jin Y, Lemasters JJ. Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat cardiomyocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2006; 290:H2024-H2034.
25. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol. 2003;549:513-524.
26. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, et al. Specific inhibition of the mitochon- drial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38:367-374.
27. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernard P. Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. J Biol Chem. 2005;280:18558-18561.
28. Clarke SJ, McStay GP, Halestrap AP. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem. 2002;277: 34793-34799.
29. Khaspekov L, Friberg H, Halestrap A, Viktorov I, Wieloch T. Cyclosporin A and its nonimmunosuppressive analogue N-Me-Val-4-cyclosporin A mitigate glucose/oxygen deprivation- induced damage to rat cultured hippocampal neurons. Eur J Neurosci. 1999;9:3194-3198.
30. Li Y, Johnson N, Capano M, Edwards M, Crompton M. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J. 2004;383:101-109.
31. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658-662.
32. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:652-658.
33. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: the essential role of the mito-chondrial permeability transition pore. Cardiovasc Res. 2007;75: 530-535.
34. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M. Isoflurane postconditioning prevents opening of the mito- chondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology. 2005;103:987-995.
35. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460.
36. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS. Glycogen synthase kinase-3/β (GSK3/β) binds to and promotes the actions of p53. J Biol Chem. 2003;278:48872-48879.
37. Venkatapuram S, Wang C, Krolikowski JG, Weihrauch D, Kersten JR, Warltier DC, et al. Inhibition of apoptotic protein p53 lowers the threshold of isoflurane-induced cardioprotection during early reperfusion in rabbits. Anesth Analg. 2006;103: 1400-1405.
38. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54:2360-2364.
39. Miki T, Miura T, Tsuchida A, Nakano A, Hasegawa T, Fukuma T, et al. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation. 2000;102: 458-463.
40. Miki T, Miura T, Tanno M, Sakamoto J, Kuno A, Genda S, et al. Interruption of signal transduction between G protein and PKC-e underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts. Mol Cell Biochem. 2003;247:185-193.
41. Miki T, Miura T, Yano T, Takahashi A, Sakamoto J, Tanno M, et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther. 2006;317:68-75.
42. Miki T, Tanno M, Yano T, Satoh T, Hotta H, Ohori K, et al. Modification of Akt/GSK-3/β signaling and mitochondrial GSK-3β by ER stress underlies failure of erythropoietin to protect diabetic hearts. [Abstrac] Circulation. 2007;116:11-164.
43. Miura T, Yellon DM, Hearse DJ, Downey JM. Determinants of infarct size during permanent occlusion of a coronary artery in the closed chest dog. J Am Coll Cardiol. 1987;9:647-654.
44. Miura T, Yoshida S, Limura O, Downey JM. Dobutamine modifies myocardial infarct size through supply-demand balance. Am J Physiol. 1988;254:H855-H861.
45. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol. 2008;103:501-513.
46. Barillas R, Friehs I, Cao-Danh H, Martinez JF, del Nido PJ. Inhibition of glycogen synthase kinase-3β improves tolerance to ischemia in hypertrophied hearts. Ann Thorac Surg. 2007;84: 126-133.